Clinical evaluation of lapatinib therapy in metastatic breast cancer using the bayes meta-analysis

Keyphrases

• Meta-analysis 100%
• Clinical Evaluation 100%
• Human Epidermal Growth Factor Receptor 2 (HER2) 100%
• Metastatic Breast Cancer 100%
• Lapatinib 100%
• Bayes 100%
• Clinical Benefit Rate 83%
• 95% Confidence Interval 66%
• Number-needed-to-treat 66%
• Overall Survival 50%
• Hazard Ratio 50%
• Odds Ratio 33%
• Monte Carlo Method 16%
• Randomized Controlled Trial 16%
• Treatment Efficacy 16%
• Exclusion Criteria 16%
• Published Data 16%
• Markov Chain Monte Carlo 16%
• Randomized Controlled Clinical Trial 16%
• WinBUGS 16%

Nursing and Health Professions

• Meta Analysis 100%
• Clinical Evaluation 100%
• Metastatic Breast Cancer 100%
• Gamma Urogastrone 100%
• Epidermal Growth Factor Receptor 2 100%
• Lapatinib 100%
• Clinical Trial 100%
• Confidence Interval 66%
• Numbers Needed to Treat 66%
• Overall Survival 50%
• Hazard Ratio 50%
• Odds Ratio 33%
• Efficacy 16%
• Monte Carlo Method 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Gamma Urogastrone 100%
• Epidermal Growth Factor Receptor 2 100%
• Lapatinib 100%
• Metastatic Breast Cancer 100%
• Number Needed to Treat 66%
• Overall Survival 50%
• Randomized Controlled Trial 16%
• Controlled Clinical Trial 16%